Five-Year Data Supports Safety and Tolerability of Maralixibat in ALGS
Data presented by Mirum Pharmaceuticals at the virtual 2021 International Liver Congress demonstrated the safety and tolerability of maralixibat during 5 years of treatment in patients with Alagille syndrome (ALGS). Mirum also presented results of a multinational survey of patients with intrahepatic cholestasis of pregnancy (ICP), which showed the considerable burden of ICP and emphasized…